The United States Supreme Court has agreed to hear a case that pits federal pesticide labeling regulations against state-level requirements, a decision that could have far-reaching implications for the agrochemical industry and regulatory balance. At the core of the matter is the question of whether federal law, specifically the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), trumps state laws that may require additional warnings on product labels about potential health risks, such as cancer. The case, Monsanto Company v. Durnell, brings into sharp focus the controversial herbicide glyphosate, the primary ingredient in Monsanto’s Roundup weedkiller.
The litigation traces back to 2015 when the International Agency for Research on Cancer, part of the World Health Organization, classified glyphosate as “probably carcinogenic to humans,” sparking a wave of lawsuits against Monsanto. Although the U.S. Environmental Protection Agency (EPA) has consistently found glyphosate safe for use without a cancer warning on its label, John Durnell, a plaintiff from Missouri, convinced a state jury that Monsanto should have warned consumers of potential risks, a stance later upheld by the Missouri Court of Appeals. Monsanto argues that since the EPA has not necessitated a warning, state-led misbranding claims are preempted by federal law, specifically in the cases of pesticide labeling under FIFRA (FIFRA).
The Supreme Court’s review follows a marked division among various state and federal courts regarding the extent of states’ rights to impose labeling requirements that differ from or add to federal stipulations. The U.S. federal government, through a friend-of-the-court brief, has also backed Monsanto’s position, advocating for uniformity to avoid confusion and maintain the EPA’s determinations as the guiding standard for label warnings.
As noted in their brief on the merits, Monsanto’s legal team argues that allowing non-expert juries to overrule comprehensive EPA reviews of glyphosate undermines FIFRA’s intended regulatory scheme. They assert that this could potentially lead to a patchwork of state requirements that complicate interstate commerce and innovation in agrochemicals.
The hearing comes amid significant developments for Monsanto’s parent company, Bayer, which proposed a $7.25 billion settlement to address current and future lawsuits concerning Roundup (Bloomberg). Observers note that the settlement could mitigate financial exposure should the Court rule contrary to Monsanto’s interests. The decision of this pivotal case is anticipated by early July, potentially reshaping the regulatory landscape for pesticide labeling at both state and federal levels.